Background Recent clinical trials have suggested that therapy with angiotensin-converting enzyme inhibitors in asymptomatic patients with reduced left ventricular (LV) function can significantly reduce the incidence of congestive heart failure compared with patients receiving placebo. In the present study, we examined the effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of LV systolic dysfunction and LV chamber enlargement in dogs with reduced LV ejection fraction (EF).
function can significantly reduce the incidence of congestive heart failure compared with patients receiving placebo. In the present study, we examined the effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of LV systolic dysfunction and LV chamber enlargement in dogs with reduced LV ejection fraction (EF).
Methods and Results LV dysfunction was produced in 28 dogs by multiple sequential intracoronary microembolizations. Embolizations were discontinued when LVEF was 30% to 40%. Three weeks after the last embolization, dogs were randomized to 3 months of oral therapy with enalapril (10 mg twice daily, n=7), metoprolol (25 mg twice daily, n=7), digoxin (0.25 mg once daily, n=7), or no treatment (control, n=7). As Recent clinical studies have focused on the introduction of early therapy in asymptomatic patients with reduced LV performance in an attempt to prevent this "autoinduction" of LV dysfunction and therefore avoid or, at the very least, retard the progression toward overt heart failure.'2 In the prevention arm of the SOLVD (Studies of Left Ventricular Dysfunction) trial, longterm treatment of asymptomatic patients with reduced LV ejection fraction (.35%) with the angiotensinconverting enzyme (ACE) inhibitor enalapril significantly reduced the incidence of congestive heart failure and the rate of associated hospitalizations compared with placebo-treated patients. 12 In asymptomatic patients with reduced LV ejection fraction (c40%) after myocardial infarction who were treated long-term with the ACE inhibitor captopril, the SAVE (Survival and Ventricular Enlargement) trial showed improvement in survival and reduced incidence of congestive heart failure compared with placebo-treated patients. 13 The results of these clinical trials clearly indicate that early treatment with ACE inhibitors in patients with reduced LV ejection fraction has beneficial effects on long-term outcome. It should be recognized that in all of these studies, because of the nature of clinical trials, ACE inhibitors were examined in the presence of other concommitant medications that frequently included P-blockers, calcium channel blockers, vasodilators, digitalis, and diuretics.12,3 The present study was designed to determine the effects of monotherapy with the ACE inhibitor enalapril, the p-blocker metoprolol, and the digitalis preparation digoxin on the progression of LV systolic dysfunction and dilation in dogs with reduced LV ejection fraction.
Methods Preparation of the Animal Model
Twenty-eight healthy mongrel dogs weighing between 18 and 31 kg were used in the study. Chronic LV dysfunction was produced by multiple sequential intracoronary embolizations with polystyrene latex microspheres (77 to 102 gm in diameter), as previously described.'4 Coronary microembolizations were performed during sequential cardiac catheterizations under general anesthesia and sterile conditions. The anesthesia regimen used in the present study consisted of a combination of intravenous injections of oxymorphone hydrochloride (0.22 mg/kg), diazepam (0.17 mg/kg), and sodium pentobarbital (150 to 250 mg to effect). This anesthesia regimen was effective in preventing the tachycardia, hypertension, and myocardial depression often seen in dogs anesthetized with pentobarbital alone. To determine the effects of anesthesia on LV function, two-dimensional echocardiograms were obtained in four untreated dogs with heart failure (not included in the present study) before anesthesia (conscious state) and after induction of anesthesia. A midpapillary LV short-axis crosssectional view was used to calculate the percent fractional area of shortening (FAS) defined as the difference between the end-diastolic area and the end-systolic area divided by the end-diastolic area times 100. There was no difference between FAS measured before anesthesia (34±2%) compared with that measured after induction of anesthesia (35±2%). In all dogs, coronary microembolizations were discontinued when LV ejection fraction, determined angiographically, was between 30% and 40%. To achieve this target ejection fraction, dogs underwent an average of 5.3 microembolization procedures performed over an average period of 8.8 weeks. Microembolization procedures were performed 1 to 3 weeks apart. Left ventriculograms were performed before each embolization procedure to assess ejection fraction.
Study Protocol
Three weeks after the last embolization procedure, all dogs underwent a prerandomization left and right heart catheterization. The 3-week period between the last embolization and the prerandomization cardiac catheterization procedure was allowed to ensure that all infarctions produced by the last embolization were completed. One day after cardiac catheterization, dogs were randomized to 3 months of oral monotherapy with enalapril (10 mg twice daily, n=7), metoprolol (25 mg twice daily, n=7), digoxin (0.25 mg once daily, n=7), or no treatment at all (control arm, n=7). None of the dogs in any of the four study groups received any medication aside from the specified study drugs during the 3-month follow-up period. Hemodynamic, angiographic, and neurohormonal measurements were made at baseline, before any embolizations, and were repeated 1 day before randomization and initiation of therapy and 3 months after initiating therapy. All hemodynamic and angiographic measurements were made during cardiac catheterizations. Dogs were killed after the final hemodynamic study (3 months after initiating therapy). The study was approved by the Henry Ford Hospital Care of Experimental Animals Committee and conformed to the guiding principles of the American Physiological Society.
Study End Points
The primary study end point was progression of LV systolic dysfunction based on LV ejection fraction determined angiographically. A secondary end point was progression of LV chamber dilation based on (1) a progressive increase of LV end-systolic volume and (2) a progressive increase of LV end-diastolic volume.
Hemodynamic Measurements
Aortic and LV pressures were measured with cathetertipped micromanometers (Millar Instruments). Mean pulmonary artery wedge pressure and mean right atrial pressure were measured using a Swan-Ganz catheter in conjunction with a P23 XL pressure transducer (Spectramed). Cardiac output was measured in triplicate using the thermodilution method. LV stroke volume was calculated as the ratio of cardiac output to heart rate. Systemic vascular resistance was calculated as the difference between mean aortic pressure and mean right atrial pressure times 80 divided by cardiac output. Left ventricular end-diastolic wall stress was calculated according to the equation '5 Wall stress=Pb/h(1-h/2b)(1-hb/2a2) where P is LV end-diastolic pressure, a is LV major semiaxis, b is LV minor semiaxis, and h is LV wall thickness. LV wall thickness and the major and minor semiaxes were measured from echocardiograms obtained during each study cardiac catheterization, as previously described. 16 
Ventriculographic Measurements
Single-plane left ventriculograms were obtained during each cardiac catheterization after completion of the hemodynamic measurements with the dog placed on its right side. Ventriculograms (approximately 600 right anterior oblique projection) were recorded on 35 mm cinefilm at 30 frames per second during the injection of 20 mL of contrast material (Hypaque meglumine 60%, Winthrop Pharmaceuticals). Correction for image magnification was made with a radiopaque calibrated grid placed at the level of the left ventricle. LV end-systolic and end-diastolic volumes were calculated from ventricular silhouettes using the area-length method. 17 The LV ejection fraction was calculated as the ratio of the difference of end-diastolic volume and end-systolic volume to end-diastolic volume times 100. Extrasystolic and postextrasystolic beats were excluded from all analyses involving ventriculograms.
Neurohormonal Assessments
Venous blood samples were obtained from conscious dogs 1 day before cardiac catheterization for evaluation of the plasma concentration of several neurohormones. To minimize any possible variations, blood samples were obtained between 9:00 and 10:00 AM with the dogs in a fasting state. Plasma norepinephrine concentration was measured using aluminum oxide absorption by high-performance liquid chromatography. In our laboratory, this technique has a day-to-day coefficient of variation of 6.8%. Plasma renin activity was evaluated by radioimmunoassay for generation of angiotensin-I based on modification of the method of Haber et al. 18 Immunoreactive atrial natriuretic factor in plasma was determined by radioimmunoassay as described by Shenker et al. 19 Venous blood samples were obtained once a week from dogs treated with digoxin and used for determination of plasma digoxin level.
Data Analysis Intragroup Comparisons
The primary objective of the study was to determine the effects of long-term monotherapy with enalapril, metoprolol, or digoxin on the progression of LV systolic dysfunction and dilation. Accordingly, comparisons of each hemodynamic, 
Results
All dogs entered into the study had hemodynamic, angiographic, and neurohormonal findings that were within the normal range for dogs in our laboratory. These data, obtained at baseline, before any embolizations, are shown in Tables 1 and 2 for all four study groups. There were no significant differences in any of the baseline parameters between dogs that were subsequently randomized to no treatment and dogs randomized to active treatment with enalapril, metoprolol, or digoxin. Furthermore, there were no significant differences in any of the hemodynamic, angiographic, and neurohormonal variables measured just before randomization, and the initiation of therapy between dogs randomized to no treatment and dogs randomized to treatment with enalapril, metoprolol, or digoxin. These data are shown in Tables 3 and 4 and Figs 1 through 3.
Effects of No Treatment on the Progression of LV Dysfunction and Dilation
In dogs randomized to no treatment (control arm), LV ejection fraction decreased significantly during the 3-month follow-up period (36±1% versus 26±1%, P<.001) (Fig 1) . The decline in LV ejection fraction was accompanied by a progressive increase in LV end-systolic volume (39±4 versus 57±6 mL, P<.001) (Fig 2) and LV end-diastolic volume (61±6 versus 78±8 mL, P<.002) (Fig 3) . Lack of therapy in this group of dogs during the 3-month follow-up period was associated with a significant reduction of LV stroke volume and significant increases of heart rate, mean aortic pressure, systemic vascular resistance, and plasma norepinephrine concentration (Tables  3 and 4) . LV end-diastolic wall stress, plasma renin activity, and plasma atrial natriuretic factor were not significantly different at the end of the 3-month follow-up period compared with the start of the follow-up period (Tables 3 and 4) .
Effects of Monotherapy With Enalapril
In dogs treated with enalapril, LV ejection fraction was 35±1% before the initiation of therapy and remained essentially unchanged at 38±3% after comple- (Figs 3 and 4) . volume, whereas heart rate, mean aortic pressure, sysTherapy with metoprolol was associated with a signifitemic vascular resistance, LV end-diastolic wall stress, cant reduction of LV end-diastolic pressure and LV and plasma norepinephrine concentration were not end-diastolic wall stress, whereas heart rate, mean significantly altered (Tables 3 and 4) . As metoprolol therapy, but these changes were not statistically significant (Table 4) .
Effects of Monotherapy With Digoxin
The average plasma digoxin level over the 3-month therapy period was 0.96±0.11 ng/mL. In dogs treated with digoxin, LV ejection fraction was 35+±1% before the initiation of therapy and remained essentially unchanged at 34±1% after completion of 3 months of therapy (Fig 1) . In contrast to therapy with enalapril and metoprolol, monotherapy with digoxin did not prevent progressive LV dilation. In these dogs, LV end-systolic volume measured after completion of therapy (52±4 mL) was significantly greater than before therapy (43+±4 mL) (P< .008) (Fig 2) . Similarly, LV end-diastolic volume was greater after therapy compared with before therapy (79±5 versus 67±6 mL) (P< .001) (Fig 3) . Monotherapy with digoxin had no significant effects on heart rate, mean aortic pressure, LV end-diastolic pressure, stroke volume, systemic vascular resistance, LV end-diastolic wall stress, plasma norepinephrine concentration, plasma renin activity, or plasma atrial natriuretic factor (Tables 3 and 4 were compared with the control group. The probability values are shown in Tables 5 and 6 . LV ejection fraction was significantly higher in all three treatment groups in comparison to controls. LV end-diastolic volume was lower than control in the enalapril-treated group and the metoprolol-treated group but not in the digoxintreated group. LV end-systolic volume was significantly lower than control in all three treated groups. Although significantly lower than control, end-systolic volume in the digoxin-treated group was substantially higher than that observed in the enalapril-and metoprolol-treated groups (Fig 2) . Heart rate and stroke volume were significantly lower than control only in the enalapril and metoprolol groups (Table 5 ). Systemic vascular resistance was lower than control (marginally significant) only in the enalapril-and metoprolol-treated groups. LV end-diastolic pressure and wall stress were lower than control (marginally significant) only in the metoprolol-treated group (Table 5) . Plasma norepinephrine concentration was lower than control (marginally significant) only in the digoxin-treated group (Table 6 ). Atrial natriuretic factor was not significantly different than controls in any of the three treated groups (Table 6 ). Discussion Consistent with our previous studies,1420 the results of the present study indicate that in the absence of any therapeutic interventions, progressive deterioration of LV systolic function and progressive LV chamber dilation occur in dogs with reduced LV ejection fraction resulting from loss of viable LV myocardium. In contrast, dogs with reduced LV ejection fraction randomized to early monotherapy with enalapril or metoprolol did not manifest progressive LV systolic dysfunction or progressive LV chamber enlargement. The results also indicate that early therapy with digoxin, although effective in maintaining LV ejection fraction, does not appear to have a beneficial impact on progressive LV enlargement.
The observation of this study that monotherapy with enalapril prevents the progressive deterioration of LV systolic function and LV chamber enlargement is consistent with the results and supports the conclusions of several recent clinical trials.'2"l3 In the prevention arm of the SOLVD trial, early treatment with enalapril in asymptomatic patients with reduced LV ejection frac- HR indicates heart rate; AoP, aortic pressure; LVEDP, left ventricular end-diastolic pressure; SV, stroke volume; PAWP, pulmonary artery wedge pressure; SVR, systemic vascular resistance; LV, left ventricular; EF, ejection fraction; ESV, end-systolic volume; and EDV, end-diastolic volume.
tion was shown to reduce the incidence of congestive heart failure and associated hospitalizations as well as a trend toward fewer deaths due to cardiovascular causes compared with patients given placebo.12 In a subset of patients with mild to moderate heart failure and reduced LV ejection fraction (c35%) enrolled in the treatment arm of the SOLVD trial, long-term treatment with enalapril also was shown to prevent progressive LV enlargement compared with patients randomized to placebo.3 In this subset study, patients randomized to placebo manifested a significant increase in LV end-diastolic and end-systolic volumes, whereas patients randomized to enalapril manifested modest but significant improvements in LV end-systolic and end-diastolic volumes and LV ejection fraction after 1 year of therapy. 3 In patients with a first anterior myocardial infarction and reduced LV ejection fraction (<45%), early therapy with captopril also was shown to attenuate the process of progressive LV dilation. 21 Unlike In patients with symptomatic heart failure due to dilated cardiomyopathy and an average LV ejection fraction of 25%, a 3-month treatment with bucindolol resulted in improvement of LV ejection fraction and New York Heart Association (NYHA) functional class compared with patients randomized to placebo. 24 In patients with severe heart failure due to ischemic cardiomyopathy with an average LV ejection fraction of 23%, long-term therapy with metoprolol was associated with marked improvement of LV ejection fraction. 26 As with all of these clinical studies, early long-term therapy with metoprolol in the present study was also associated with a significant increase of LV ejection fraction.
As with ,B-blockers, there are no major clinical trials to date that have examined the effects of early digoxin therapy on the progression of LV dysfunction and dilation in asymptomatic patients with reduced LV ejection fraction. The results of the present study suggest that early long-term monotherapy with digoxin in dogs with reduced LV ejection fraction prevents the progressive decline in LV ejection fraction but does not impede the process of progressive LV dilation. These observations are consistent with observations made in a recent study of patients with anterior myocardial infarction.28 In this study, 40 patients were randomized to features of the failing heart and are manifested in the canine model of heart failure used in this study.14,36 Modulation of afterload also must be considered in the beneficial effects of 3-blockers in heart failure. In the present study, long-term metoprolol therapy also attenuated the rise in systemic vascular resistance seen in untreated dogs. 1-Blockers also have been shown to increase myocardial 13-adrenoceptor density and improve the contractile response to catecholamine stimulation in patients with heart failure.37 The observed beneficial effects of metoprolol also may have been derived in part from improvement in myocardial oxygen consumption, a feature commonly associated with this class of drugs.38 In the present study, metoprolol therapy prevented the rise in heart rate and attenuated the rise in LV wall stress seen in untreated dogs, both of oxygen consumption. Although global ischemia, based on myocardial lactate release, does not appear to be present in the microembolization model of heart failure used in this study, the presence of ongoing undetectable focal ischemia cannot be excluded.39 Accordingly, one cannot exclude the possibility that the observed beneficial effects of metoprolol therapy also could have resulted in part from an improvement in the coronary supply-demand balance. Unlike enalapril and metoprolol, digoxin therapy did not impede the process of progressive LV enlargement. Long-term digoxin therapy had little or no effect on heart rate or systemic vascular resistance when compared with untreated dogs. One possible explanation for the seemingly discordant effect of digoxin on LV systolic function and dilation may be that digoxin, in this setting, acts primarily as an inotropic agent, thus helping maintain LV ejection fraction but not affording substantial protection against progressive LV dilation.
Conclusions
The results of the present study indicate that in dogs with reduced LV ejection fraction, early long-term monotherapy with enalapril or metoprolol prevents the progressive deterioration of LV systolic function and arrests or attenuates the process of progressive LV chamber enlargement. In contrast, early therapy with digoxin, while preventing the progressive decline in LV ejection fraction, does not impede the process of progressive LV chamber dilation. Additional investigations focusing on the morphological, cellular, and biochemical consequences of early therapy with ACE inhibitors, ,8-blockers, or digitalis preparations are needed to gain further insight into the specific mechanisms of action of each of these classes of compounds, with respect to their influence on the process of progressive LV dysfunction and dilation.
